Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

Hernia repair is one of the most common operations. Whilst there are few complications, pain may last for several weeks and extend the period of convalescence. ALGRX 4975 is an ultra-pure form of capsaicin, which is a pain medicine that has the potential for long-term pain relief following a single administration. This study will determine whether ALGRX 4975 can provide pain relief following hernia repair.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AlgoRx Pharmaceuticals

Criteria

Inclusion Criteria:

• The subject has a primary hernia and will undergo hernia repair by standard Lichtenstein mesh repair.

Exclusion Criteria:

• The subject has undergone a lower abdomen surgical procedure in the past.

• The subject is currently scheduled to undergo bilateral inguinal hernia repair.

• Personal or familial contraindications in undergoing general anesthesia.

• Systolic blood pressure greater than 150 mmHg or diastolic greater than 95 mmHg